[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Opko Health Inc (OPK)

Opko Health Inc (OPK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,072,231
  • Shares Outstanding, K 755,092
  • Annual Sales, $ 606,880 K
  • Annual Income, $ -225,680 K
  • EBIT $ -24 M
  • EBITDA $ 73 M
  • 60-Month Beta 1.50
  • Price/Sales 1.75
  • Price/Cash Flow N/A
  • Price/Book 0.88

Options Overview Details

View History
  • Implied Volatility 96.57% (-47.20%)
  • Historical Volatility 41.93%
  • IV Percentile 28%
  • IV Rank 6.53%
  • IV High 713.69% on 03/11/26
  • IV Low 53.43% on 08/22/25
  • Expected Move (DTE 28) 0.0425 (2.99%)
  • Put/Call Vol Ratio 0.84
  • Today's Volume 112
  • Volume Avg (30-Day) 400
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 35,570
  • Open Int (30-Day) 33,854
  • Expected Range 1.3775 to 1.4625

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 5
  • High Estimate $-0.07
  • Low Estimate $-0.08
  • Prior Year $-0.19
  • Growth Rate Est. (year over year) +57.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1300 +25.66%
on 05/19/26
1.5500 -8.39%
on 06/05/26
+0.2900 (+25.66%)
since 05/18/26
3-Month
0.9769 +45.36%
on 04/29/26
1.5500 -8.39%
on 06/05/26
+0.2500 (+21.37%)
since 03/18/26
52-Week
0.9769 +45.36%
on 04/29/26
1.6000 -11.25%
on 10/06/25
+0.1300 (+10.08%)
since 06/18/25

Most Recent Stories

More News
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society’s annual...

OPK : 1.4200 (+0.71%)
OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models  Data will be presented at the American Society of Gene & Cell...

OPK : 1.4200 (+0.71%)
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an amendment to its agreement with...

OPK : 1.4200 (+0.71%)
BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

ELMWOOD PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the launch...

OPK : 1.4200 (+0.71%)
OPKO Health: Q1 Earnings Snapshot

OPKO Health: Q1 Earnings Snapshot

OPK : 1.4200 (+0.71%)
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the...

OPK : 1.4200 (+0.71%)
OPKO Health's Diagnostics Dependency Meets Growing Questions About Lab Volume Trajectory

Barchart Research What to Expect from OPK Earnings OPK Generated April 27, 2026 Current Price $1.2000 EPS Estimate $$-0.07 Consensus Rating Moderate Buy Average Move 4.81% OPKO Health's Diagnostics Dependency...

OPK : 1.4200 (+0.71%)
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of Hematology...

OPK : 1.4200 (+0.71%)
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026

MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S. financial...

OPK : 1.4200 (+0.71%)
OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19

WESTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial...

OPK : 1.4200 (+0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and...

See More

Key Turning Points

3rd Resistance Point 1.5000
2nd Resistance Point 1.4800
1st Resistance Point 1.4500
Last Price 1.4200
1st Support Level 1.4000
2nd Support Level 1.3800
3rd Support Level 1.3500

See More

52-Week High 1.6000
Last Price 1.4200
Fibonacci 61.8% 1.3620
Fibonacci 50% 1.2885
Fibonacci 38.2% 1.2149
52-Week Low 0.9769

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.